Literature DB >> 20689266

Androgen replacement therapy in late-onset hypogonadism: current concepts and controversies - a mini-review.

Juuso I Mäkinen1, Ilpo Huhtaniemi.   

Abstract

BACKGROUND: Normal testicular function is essential for the maintenance of male physical strength and behaviour irrespective of age. A new term of late-onset hypogonadism (LOH) has been coined for the condition of decreased testosterone (T) and hypogonadal symptoms in ageing men.
OBJECTIVE: The most important testicular hormone, T, is responsible for the gender-specific androgenic-anabolic effects in men. Testicular T production remains stable until around the age of 40 years after which it declines by 1-2% annually. Despite this age-related decline, serum T levels in most older men remain within the reference range of younger men. The decreasing androgen levels are paralleled by well-defined objective biological and nonspecific subjective signs and symptoms of ageing. Because these symptoms are similar to those observed in young men with documented hypogonadism, androgen replacement therapy (ART) has been considered a logical way to treat them.
METHODS: A thorough review of the existing literature was performed to evaluate the current concepts and controversies related to ageing men and ART.
RESULTS: Although it is intuitively logical that the symptoms of LOH are due to the ageing-related deficiency of T, and that they can be reversed by ART, the evidence for this is still variable and often weak. In particular, evidence-based information about long-term benefits and risks of ART in ageing men is largely missing.
CONCLUSIONS: Despite widespread use, evidence-based proof for the objective benefits and side effects of ART of elderly men is still scanty, and such treatments should be considered experimental.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689266     DOI: 10.1159/000319635

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  6 in total

Review 1.  The treatment of late-onset hypogonadism.

Authors:  Oktay Üçer; Bilal Gümüş
Journal:  Turk J Urol       Date:  2014-03-24

2.  Autophagic deficiency is related to steroidogenic decline in aged rat Leydig cells.

Authors:  Wei-Ren Li; Liang Chen; Zhi-Jie Chang; Hua Xin; Tao Liu; Yan-Quan Zhang; Guang-Yong Li; Feng Zhou; Yan-Qing Gong; Zhe-Zhu Gao; Zhong-Cheng Xin
Journal:  Asian J Androl       Date:  2011-08-08       Impact factor: 3.285

3.  Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.

Authors:  Keisuke Okada; Hideaki Miyake; Takaki Ishida; Kenta Sumii; Noritoshi Enatsu; Koji Chiba; Kei Matsushita; Masato Fujisawa
Journal:  Am J Mens Health       Date:  2016-06-02

4.  Discovery of methylpyrimidine ring-fused diterpenoid analogs as a novel testosterone synthesis promoter.

Authors:  Jie Bai; Jia Xie; Li-Ting Wang; Yajing Xing; Qian-Ru Jiang; Fan Yang; Jie Tang; Zhengfang Yi; Wen-Wei Qiu
Journal:  RSC Adv       Date:  2019-03-27       Impact factor: 4.036

5.  Effects of velvet antler polypeptide on sexual behavior and testosterone synthesis in aging male mice.

Authors:  Zhi-Jun Zang; Hong-Feng Tang; Ying Tuo; Wei-Jie Xing; Su-Yun Ji; Yong Gao; Chun-Hua Deng
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

6.  Protective effect of calretinin on testicular Leydig cells via the inhibition of apoptosis.

Authors:  Wendan Xu; Qian Zhu; Bei Zhang; Shan Liu; Xiaonan Dai; Chao Gao; Li Gao; Yugui Cui
Journal:  Aging (Albany NY)       Date:  2017-04       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.